iPSC disease modeling presents unique advantages over other traditional methods, such as primary cells, other cell lines, and animal models. Primary cells are limited by their short lifespan and variable performance, while other cell lines often lack the genetic background of the disease. Animal models, while useful, cannot fully replicate human biology and disease states.

iPSC-derived models, on the other hand, overcome these barriers. They are patient-specific, enabling the recapitulation of complex genetic backgrounds and diseases. As a result, iPSC models offer superior physiological relevance in studies related to neurodegenerative diseases, such as ALS (using ALS iPSCs) and Alzheimer's disease (using stem cells).

Elixirgen Scientific provides tailored solutions to mitigate these hurdles. They assist in pinpointing which iPSC banks might hold the disease-specific lines relevant to the client's interests and aid in streamlining the acquisition process from these banks. However, it's important to keep in mind that there could be unexpected obstacles along the way (check this page to learn about our experiences). Leveraging their proficiency in iPSC culture and differentiation, Elixirgen Scientific is capable of creating a wide array of downstream assays with consistent outcomes. Their bespoke differentiation technology further empowers the creation of various cell types, leading to a more thorough approach in disease modeling.